Cargando…

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Characterization of human monoclonal antibodies is providing considerable insight into mechanisms of broad HIV-1 neutralization. Here we report an HIV-1 gp41 membrane-proximal external region (MPER)-specific antibody, named 10E8, which neutralizes ~98% of tested viruses. An analysis of sera from 78...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jinghe, Ofek, Gilad, Laub, Leo, Louder, Mark K., Doria-Rose, Nicole A., Longo, Nancy S., Imamichi, Hiromi, Bailer, Robert T., Chakrabarti, Bimal, Sharma, Shailendra K., Alam, S. Munir, Wang, Tao, Yang, Yongping, Zhang, Baoshan, Migueles, Stephen A., Wyatt, Richard, Haynes, Barton F., Kwong, Peter D., Mascola, John R., Connors, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854285/
https://www.ncbi.nlm.nih.gov/pubmed/23151583
http://dx.doi.org/10.1038/nature11544
Descripción
Sumario:Characterization of human monoclonal antibodies is providing considerable insight into mechanisms of broad HIV-1 neutralization. Here we report an HIV-1 gp41 membrane-proximal external region (MPER)-specific antibody, named 10E8, which neutralizes ~98% of tested viruses. An analysis of sera from 78 healthy HIV-1-infected donors demonstrated that 27% contained MPER-specific antibodies and 8% contained 10E8-like specificities. In contrast to other neutralizing MPER antibodies, 10E8 did not bind phospholipids, was not autoreactive, and bound cell-surface envelope. The structure of 10E8 in complex with the complete MPER revealed a site-of-vulnerability comprising a narrow stretch of highly conserved gp41-hydrophobic residues and a critical Arg/Lys just prior to the transmembrane region. Analysis of resistant HIV-1 variants confirmed the importance of these residues for neutralization. The highly conserved MPER is a target of potent, non-self-reactive neutralizing antibodies, suggesting that HIV-1 vaccines should aim to induce antibodies to this region of HIV-1 Env.